Julien Grogg, PhD, MBA - CEO of Release Therapeutics Release Tx logo Dr. Julien Grogg will Lead the Company's Transition to Clinical ...

Along with VX-880, it is also working on encapsulated islet cells as a treatment for T1D, although that programme remains in preclinical development. Encapsulation could mean doing away with the ...

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of ...

Synthesis and designing of the polymer platforms which are safe for biologics, enhance their encapsulation/loading ... as for seamless delivery of the new therapy to clinics.

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely ...

Results from rhesus macaques provide solid ground for a first-in-human investigation of heart repair with stem cell-derived ...